Alex Strongin

Summary

Affiliation: The Burnham Institute
Country: USA

Publications

  1. pmc Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis
    Sergey A Shiryaev
    Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, California, United States of America
    PLoS ONE 4:e4952. 2009
  2. pmc A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen
    Katarzyna Gawlik
    Infectious and Inflammatory Disease Center, Sanford Burnham Medical Research Institute, La Jolla, California, United States of America
    PLoS ONE 5:e11305. 2010
  3. pmc Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site
    Katarzyna Gawlik
    Burnham Institute for Medical Research, La Jolla, California, United States of America
    PLoS ONE 4:e5031. 2009
  4. pmc Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat
    Christopher C Leonardo
    Department of Molecular Pharmacology and Physiology, School of Basic Biomedical Sciences, College of Medicine, University of South Florida, Tampa, FL 33612, USA
    J Neuroinflammation 5:34. 2008
  5. ncbi request reprint Mislocalization and unconventional functions of cellular MMPs in cancer
    Alex Y Strongin
    The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Cancer Metastasis Rev 25:87-98. 2006
  6. pmc Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy
    Alex Y Strongin
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochim Biophys Acta 1803:133-41. 2010
  7. ncbi request reprint S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
    Zezong Gu
    Center for Neuroscience and Aging, Program in Cell Adhesion and Extracellular Matrix Biology, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 297:1186-90. 2002
  8. ncbi request reprint Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation
    Vladislav S Golubkov
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    J Biol Chem 282:36283-91. 2007
  9. doi request reprint Rhodanine derivatives as selective protease inhibitors against bacterial toxins
    Sherida L Johnson
    Infectious and Inflammatory Disease Center and Cancer Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Chem Biol Drug Des 71:131-9. 2008
  10. ncbi request reprint Prostaglandin FP agonists alter metalloproteinase gene expression in sclera
    Robert N Weinreb
    Hamilton Glaucoma Center and Department of Ophthalmology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 9209 0946, USA
    Invest Ophthalmol Vis Sci 45:4368-77. 2004

Research Grants

  1. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Y Strongin; Fiscal Year: 2010
  2. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2009
  3. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2009
  4. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 2001
  5. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2005
  6. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2004
  7. Structure-based Drug Design for Smallpox Therapy
    Alex Strongin; Fiscal Year: 2007
  8. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 1999
  9. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2007
  10. Hydroxamate-based therapy to target T cell homing in IDDM
    Alex Strongin; Fiscal Year: 2007

Collaborators

  • Elena I Deryugina
  • Jeffrey W Smith
  • Peter C Baciu
  • Stuart A Lipton
  • Donald Guiney
  • Maurizio Pellecchia
  • Zezong Gu
  • Yingxiao Wang
  • Robert Day
  • Robert N Weinreb
  • Boguslaw Stec
  • Michael J Duffy
  • Boxu Yan
  • Dmitri V Rozanov
  • Vladislav S Golubkov
  • Albert G Remacle
  • Alexei Y Savinov
  • Sergey A Shiryaev
  • Katarzyna Gawlik
  • Alexei V Chekanov
  • Andrei V Chernov
  • Tatiana I Postnova
  • Boris I Ratnikov
  • Ilian A Radichev
  • Natalia D Marchenko
  • George N Marchenko
  • Nor Eddine Sounni
  • Khatereh Motamedchaboki
  • Roy Williams
  • Sherida L Johnson
  • Piotr Cieplak
  • Dmitry V Rozanov
  • Wenhong Zhu
  • Roxane Desjardins
  • Alexander E Aleshin
  • Christopher C Leonardo
  • Stan Krajewski
  • Stephen J Doxsey
  • Stephen Tomlinson
  • Albert Remacle
  • Wei Li
  • Elena I Shagisultanova
  • Edward Z Monosov
  • Katarina Wolf
  • Berhane Ghebrehiwet
  • Agnes Noel
  • Svetlana Baranovskaya
  • Mingxing Ouyang
  • Dustin R Wakeman
  • Evan Y Snyder
  • Angela N Purves
  • Stefan Vasile
  • Tatiana N Shiryaeva
  • Michele F Rega
  • Eduard A Sergienko
  • Olga L Rozanova
  • Alexei M Eroshkin
  • Natalya V Golubkova
  • Naomi J H Cotton
  • Alexei Savinov
  • Rebecca Harbach
  • Eok Soo Oh
  • Li Hsing Chen
  • Joanne M Ajmo
  • Ge Wei
  • Amelie Parent
  • Mojgan Sabet
  • Lisa A Collier
  • Michal Lebl
  • Autumn K Eakin
  • Robert C Liddington
  • Keith R Pennypacker
  • Kang Liu
  • Paul E Gottschall
  • Anupama Srinivasan
  • Ilian Radichev
  • Sergey Sikora
  • Vladimir S Akatov
  • Susan Kennedy
  • Martin Fugere
  • Maryla Krajewska
  • Andrei L Osterman
  • Sarah Boyd
  • Elizabeth Hahn-Dantona
  • Sergei R Malkhosyan
  • Stanislaw Krajewski
  • Inna A Novikova
  • Ainura Kyshtoobayeva
  • Yu Linli
  • Howard C Crawford

Detail Information

Publications46

  1. pmc Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis
    Sergey A Shiryaev
    Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, California, United States of America
    PLoS ONE 4:e4952. 2009
    ..The splice variants of the single MBP gene (Golli-MBP BG21 and J37) are widely expressed in the neurons and also in the immune cells. The relative contribution of the individual MMPs to the MBP cleavage is not known...
  2. pmc A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen
    Katarzyna Gawlik
    Infectious and Inflammatory Disease Center, Sanford Burnham Medical Research Institute, La Jolla, California, United States of America
    PLoS ONE 5:e11305. 2010
    ..In addition, the availability of the biosensor is a foundation for non-invasive monitoring of furin activity in cancer cells. Conceptually, the biosensor we developed may serve as a prototype for other proteinase-activated biosensors...
  3. pmc Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site
    Katarzyna Gawlik
    Burnham Institute for Medical Research, La Jolla, California, United States of America
    PLoS ONE 4:e5031. 2009
    ..We hypothesized that to activate profurin its prodomain had to be removed and, in addition, the emerging enzyme's N-terminus had to be ejected from the catalytic cleft...
  4. pmc Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat
    Christopher C Leonardo
    Department of Molecular Pharmacology and Physiology, School of Basic Biomedical Sciences, College of Medicine, University of South Florida, Tampa, FL 33612, USA
    J Neuroinflammation 5:34. 2008
    ..AG3340 (prinomastat) is an MMP inhibitor with high selectivity for the gelatinases. The purpose of this study was to determine whether these compounds could limit H-I--induced injury when administered at a delayed time point...
  5. ncbi request reprint Mislocalization and unconventional functions of cellular MMPs in cancer
    Alex Y Strongin
    The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Cancer Metastasis Rev 25:87-98. 2006
    ..It is reasonable, however, to hypothesize from these data that many individual MMPs perform in a similar manner and display a much broader range of functions compared to what we earlier thought...
  6. pmc Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy
    Alex Y Strongin
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochim Biophys Acta 1803:133-41. 2010
    ....
  7. ncbi request reprint S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
    Zezong Gu
    Center for Neuroscience and Aging, Program in Cell Adhesion and Extracellular Matrix Biology, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 297:1186-90. 2002
    ..These findings suggest a potential extracellular proteolysis pathway to neuronal cell death in which S-nitrosylation activates MMPs, and further oxidation results in a stable posttranslational modification with pathological activity...
  8. ncbi request reprint Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation
    Vladislav S Golubkov
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    J Biol Chem 282:36283-91. 2007
    ..These findings shed more light on the functional role of the inhibitory prodomain and on the proteolytic control of MT1-MMP activation, a crucial process that may be differentially regulated in normal and cancer cells...
  9. doi request reprint Rhodanine derivatives as selective protease inhibitors against bacterial toxins
    Sherida L Johnson
    Infectious and Inflammatory Disease Center and Cancer Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Chem Biol Drug Des 71:131-9. 2008
    ..Integration of these results with our structure-activity relationship studies provides a framework for the development of potential drug candidates against anthrax and botulinum...
  10. ncbi request reprint Prostaglandin FP agonists alter metalloproteinase gene expression in sclera
    Robert N Weinreb
    Hamilton Glaucoma Center and Department of Ophthalmology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 9209 0946, USA
    Invest Ophthalmol Vis Sci 45:4368-77. 2004
    ..The present study was undertaken to determine whether exposure of the sclera to prostaglandin (PG)F(2alpha) or to the PGF(2alpha) analogue latanoprost acid alters mRNA for matrix metalloproteinases...
  11. ncbi request reprint O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP)
    Albert G Remacle
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    J Biol Chem 281:16897-905. 2006
    ..Overall, our results point out that there is a delicate balance between glycosylation and self-proteolysis of MT1-MMP in cancer cells and that when this balance is upset the catalytically potent MT1-MMP pool is self-proteolyzed...
  12. ncbi request reprint Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability
    Vladislav S Golubkov
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 280:25079-86. 2005
    ..We believe that our data show a novel proteolytic pathway to chromatin instability and elucidate the close association of MT1-MMP with malignant transformation...
  13. ncbi request reprint Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin
    Wei Li
    Cell Adhesion and Extracellular Matrix Biology Program, Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 64:8657-65. 2004
    ..In summary, we hypothesize that MMP-26, by cleaving and inactivating the AAT serpin, operates as a unique functional link that regulates a coordinated interplay between Ser and metalloproteinases in estrogen-dependent neoplasms...
  14. pmc Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer
    Dmitri V Rozanov
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Cancer Res 68:4086-96. 2008
    ....
  15. ncbi request reprint The cytoplasmic tail peptide sequence of membrane type-1 matrix metalloproteinase (MT1-MMP) directly binds to gC1qR, a compartment-specific chaperone-like regulatory protein
    Dmitry V Rozanov
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    FEBS Lett 527:51-7. 2002
    ....
  16. pmc Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells
    Nor Eddine Sounni
    Cancer Research Center, Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Int J Cancer 126:1067-78. 2010
    ..The TIMP-2-induced stimulation of ERK signaling in cancer cells explains the direct, as opposed to the inverse, association of TIMP-2 expression with poor prognosis in cancer...
  17. pmc Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer
    Andrei V Chernov
    Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA
    J Biol Chem 285:19647-59. 2010
    ..We suggest that the epigenetic mechanisms allow gliomas to deposit an invasion-promoting collagen-enriched matrix and then to use this matrix to accomplish their rapid migration through the brain tissue...
  18. pmc Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells
    Andrei V Chernov
    Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    J Biol Chem 284:12727-34. 2009
    ..Our results suggest that the epigenetic control plays an important role in both the balanced regulation of the MT1-MMP/MMP-2/TIMP-2 axis and the invasive behavior in cancer cells...
  19. pmc Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase
    Ilian A Radichev
    Sanford Burnham Medical Research Institute, La Jolla, California 92037, USA
    J Biol Chem 285:16076-86. 2010
    ..Because MT6-MMP has been suggested to play a role in disease, including cancer and autoimmune multiple sclerosis, the identity of its physiologically relevant cleavage targets remains to be determined...
  20. ncbi request reprint The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells
    Dmitri V Rozanov
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 279:4260-8. 2004
    ..These events implicate MT1-MMP, not only in the activation of MMP-2, but also in the mechanisms that control the subsequent fate of MMP-2 in cells and tissues...
  21. ncbi request reprint Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice
    Dmitri V Rozanov
    Cell Adhesion and Extracellular Matrix Biology, Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Cancer Res 66:6258-63. 2006
    ..We believe that our results shed additional light on the functions of MT1-MMP in cancer and clearly make this protease a promising drug target in metastatic malignancies...
  22. ncbi request reprint Proteolysis-driven oncogenesis
    Vladislav S Golubkov
    Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Cell Cycle 6:147-50. 2007
    ..We have placed the emphasis of our review on the membrane type-1 matrix metalloproteinase (MT1-MMP)-induced chromosome instability which leads to the transition from normalcy to malignancy...
  23. pmc Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
    Dmitri V Rozanov
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA, USA
    Mol Cancer Ther 8:1515-25. 2009
    ....
  24. pmc Substrate cleavage analysis of furin and related proprotein convertases. A comparative study
    Albert G Remacle
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Biol Chem 283:20897-906. 2008
    ..Our results also suggest that pathogens, including anthrax PA83 and the avian influenza A H5N1 (bird flu) hemagglutinin precursor, evolved to be as sensitive to PC proteolysis as the most sensitive normal human proteins...
  25. pmc Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis
    Sergey A Shiryaev
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    J Biol Chem 284:30615-26. 2009
    ..These data suggest that MMP-25 plays an important role in MS pathology and that MMP-25, especially because of its restricted cell/tissue expression pattern and cell surface/lipid raft localization, is a promising drug target in MS...
  26. pmc Matrix metalloproteinases, T cell homing and beta-cell mass in type 1 diabetes
    Alexei Y Savinov
    Burnham Institute for Medical Reserach, La Jolla, CA 92037, USA
    Vitam Horm 80:541-62. 2009
    ..Overall, existing experimental evidence suggests that there is a sound mechanistic rationale for clinical trials of the inhibitors of T cell MT1-MMP in human type 1 diabetes patients...
  27. pmc Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells
    Ilian A Radichev
    Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Biochem J 420:37-47. 2009
    ..Overall, it is tempting to hypothesize that by interacting with pro-invasive MT1-MMP, ANT plays a yet to be identified role in a coupling mechanism between energy metabolism and pericellular proteolysis in migrating cancer cells...
  28. ncbi request reprint Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients
    Alexei Y Savinov
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 66:2716-24. 2006
    ....
  29. ncbi request reprint Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis
    Elena I Deryugina
    The Extracellular Matrix Biology Program, The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 62:580-8. 2002
    ..Our results demonstrate that the enhanced tumorigenicity of glioma cells overexpressing MT1-MMP involves stimulation of angiogenesis through the up-regulation of VEGF production...
  30. ncbi request reprint Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif
    Natalia D Marchenko
    Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 277:18967-72. 2002
    ....
  31. pmc Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin
    George N Marchenko
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, U S A
    Biochem J 363:253-62. 2002
    ....
  32. ncbi request reprint Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms
    Dmitri V Rozanov
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 278:8257-60. 2003
    ..Finally, our data strongly imply that MT1-MMP is a likely substitute for the general proprotein convertase activity of furin-like proteinases, especially in furin-deficient cancer cells...
  33. pmc The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein
    George N Marchenko
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochem J 372:503-15. 2003
    ..MMP-21 is expressed transiently in mouse embryogenesis and increased in embryonic neuronal tissues. Our observations clearly indicate that there is an important specific function for MMP-21 in embryogenesis, especially in neuronal cells...
  34. ncbi request reprint An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase
    Boris I Ratnikov
    Burnham Institute, 10901 N Torrey Pines Road, La Jolla, California 92037, USA
    J Biol Chem 277:7377-85. 2002
    ....
  35. ncbi request reprint Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells
    Dmitri V Rozanov
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA
    Exp Cell Res 293:81-95. 2004
    ..It is tempting to hypothesize that the mechanisms involved in trafficking of MT1-MMP to caveolin-enriched lipid rafts may be targeted in a clinically advantageous manner...
  36. ncbi request reprint Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells
    Natalia D Marchenko
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92093, USA
    Int J Biochem Cell Biol 36:942-56. 2004
    ..This study brings us a step forward towards a better understanding of the unconventional role, regulation and functions of epithelial cell MMP-26 in physiological conditions and in neoplasms...
  37. ncbi request reprint The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer
    Elena I Shagisultanova
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Anticancer Res 24:199-201. 2004
    ..We performed a case-control study to test association between this polymorphism and the risk of breast cancer...
  38. ncbi request reprint Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency
    Alexei V Chekanov
    Infectious and Inflammatory Disease Center, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Arch Biochem Biophys 446:52-9. 2006
    ..Our data point to the intriguing mechanism of anthrax that appears to facilitate entry of the toxin into the cells which express limiting amounts of PCs and an incompletely processed PA83 pool...
  39. ncbi request reprint Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: potential implications for tumorigenesis
    Vladislav S Golubkov
    Cancer Research Center, The Burnham Institute for Medical Research, La Jolla, California 92037, USA
    J Biol Chem 280:42237-41. 2005
    ..Taken together, our results confirm that MT1-MMP cleaves pericentrin-2 in humans but not in mice and that mouse models of cancer probably cannot be used to critically examine MT1-MMP functionality...
  40. ncbi request reprint The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP)
    Albert G Remacle
    The Burnham Institute, La Jolla, CA 92037, USA
    J Cell Sci 118:4975-84. 2005
    ..The observed transport mechanisms provide a vehicle for the intracellular targets and, accordingly, for an intracellular cleavage function of MT1-MMP in malignant cells, which routinely overexpress this protease...
  41. ncbi request reprint A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia
    Zezong Gu
    Center for Neuroscience and Aging, The Burnham Institute, La Jolla, California 92037, USA
    J Neurosci 25:6401-8. 2005
    ..We conclude that MMP-9 is a highly promising drug target and that SB-3CT derivatives have significant therapeutic potential in stroke patients...
  42. ncbi request reprint Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system
    Dmitri V Rozanov
    The Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 279:46551-7. 2004
    ....
  43. ncbi request reprint Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin
    Dmitri V Rozanov
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Int J Biochem Cell Biol 37:142-54. 2005
    ..In addition, our study supports a unique role of furin in the activation of PA, thereby suggesting that furin inhibitors are the likely specific drugs for short-term therapy of anthrax infection...
  44. ncbi request reprint Prointegrin maturation follows rapid trafficking and processing of MT1-MMP in Furin-Negative Colon Carcinoma LoVo Cells
    Elena I Deryugina
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA
    Traffic 5:627-41. 2004
    ..Our findings argue strongly that the processing by furin is not a prerequisite for the activation of MT1-MMP...
  45. ncbi request reprint The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR
    Dmitry V Rozanov
    Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 277:9318-25. 2002
    ..It is tempting to hypothesize that these novel mechanisms may play important roles in vivo and have to be taken into account in designing hydroxamate-based cancer therapy...
  46. pmc Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis
    Katarina Wolf
    Department of Dermatology, University of Wurzburg, 97080 Wurzburg, Germany
    J Cell Biol 160:267-77. 2003
    ....

Research Grants25

  1. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Y Strongin; Fiscal Year: 2010
    ....
  2. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2009
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  3. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2009
    ..This valuable information will lead directly to the development of novel and efficient strategies for the detection, prognosis, and treatment of a broad range of pathologies. ..
  4. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 2001
    ..We anticipate that novel methods of tumor prognosis and therapy will emerge from our studies. ..
  5. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2005
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  6. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2004
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  7. Structure-based Drug Design for Smallpox Therapy
    Alex Strongin; Fiscal Year: 2007
    ..When appropriate benchmarks are met, the drug candidates will be delivered to the government for continued testing and refinement involving the variola virus. ..
  8. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 1999
    ..We anticipate that novel methods of tumor prognosis and therapy will emerge from our studies. ..
  9. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2007
    ..This valuable information will lead directly to the development of novel and efficient strategies for the detection, prognosis, and treatment of a broad range of pathologies. ..
  10. Hydroxamate-based therapy to target T cell homing in IDDM
    Alex Strongin; Fiscal Year: 2007
    ..We strongly believe that the results of our experimental program will lead to the development of new and effective anti-diabetic therapies for IDDM patients. ..
  11. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2007
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  12. MT1-MMP pericellular proteolysis in malignancy
    Alex Strongin; Fiscal Year: 2006
    ..The results of these experiments have a very high probability of providing an effective means to regulate the MT1-MMP function in the setting of the disease. ..
  13. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2005
    ..This valuable information will lead directly to the development of novel and efficient strategies for the detection, prognosis, and treatment of a broad range of pathologies. ..
  14. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2003
    ..We anticipate our studies will lead to novel methods of cancer therapy based on the modulation of ECM remodeling and inhibition of tumor angiogenesis. ..
  15. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 2000
    ..We anticipate that novel methods of tumor prognosis and therapy will emerge from our studies. ..
  16. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 2002
    ..We anticipate that novel methods of tumor prognosis and therapy will emerge from our studies. ..
  17. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2006
    ..This valuable information will lead directly to the development of novel and efficient strategies for the detection, prognosis, and treatment of a broad range of pathologies. ..
  18. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2000
    ..We anticipate our studies will lead to novel methods of cancer therapy based on the modulation of ECM remodeling and inhibition of tumor angiogenesis. ..
  19. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2001
    ..We anticipate our studies will lead to novel methods of cancer therapy based on the modulation of ECM remodeling and inhibition of tumor angiogenesis. ..
  20. METALLOPROTEINASES IN TUMOR NEOVASCULARIZATION
    Alex Strongin; Fiscal Year: 2002
    ..We anticipate our studies will lead to novel methods of cancer therapy based on the modulation of ECM remodeling and inhibition of tumor angiogenesis. ..
  21. CELL RECEPTORS DEFINE THE FATE OF MMP 2 IN CANCER
    Alex Strongin; Fiscal Year: 2003
    ..We anticipate that novel methods of tumor prognosis and therapy will emerge from our studies. ..
  22. Develop Effective Inhibitors of Anthrax Lethal Factor
    Alex Strongin; Fiscal Year: 2006
    ..We are confident that the resulting LF antagonist(s) will efficiently and safely provide the therapy that is so urgently required. ..